Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of gamma-secretase inhibitor
RO4929097 when given together with gemcitabine hydrochloride in treating patients with
advanced solid tumors. Gamma-secretase inhibitor RO4929097 may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Giving gamma-secretase inhibitor
RO4929097 together with gemcitabine hydrochloride may kill more tumor cells.